Elk Creek Partners’s PTC Therapeutics PTCT Stock Holding History

Elk Creek Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$5.15M	Sell	115,345 -144,380	-56%	-$7.27M	0.88%	48
2019 Q4	$12.5M	Sell	259,725 -106,911	-29%	-$4.54M	1.43%	15
2019 Q3	$12.4M	Buy	366,636 +76,486	+26%	+$3.33M	1.07%	26
2019 Q2	$13.1M	Sell	290,150 -177,387	-38%	-$7M	0.98%	33
2019 Q1	$17.6M	Buy	467,537 +89,863	+24%	+$3.02M	1.27%	21
2018 Q4	$13M	Buy	377,674 +106,639	+39%	+$3.83M	1.08%	30
2018 Q3	$12.7M	Buy	271,035 +2,211	+0.8%	+$91.5K	0.69%	59
2018 Q2	$9.07M	Buy	+268,824	New	+$8.38M	0.5%	88

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Elk Creek Partners's PTCT Position: Q1 2020 in Review

Elk Creek Partners reduced its PTC Therapeutics (PTCT) stake by 56% in Q1 2020, selling an estimated $7.27M and leaving 115,345 shares worth $5.15M. The position accounts for 0.88% of the portfolio, ranked #48.

Elk Creek Partners first reported a position in PTCT in Q2 2018 and has held it in 8 quarters since. The position peaked at $17.6M in Q1 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

Elk Creek Partners held 115,345 shares of PTC Therapeutics worth $5.15M as of Q1 2020.
Elk Creek Partners sold 144,380 PTC Therapeutics shares in Q1 2020, an estimated $7.27M.
PTC Therapeutics made up 0.88% of Elk Creek Partners's portfolio in Q1 2020, its #48 holding.
Elk Creek Partners first reported a position in PTC Therapeutics in Q2 2018 and has held it in 8 quarters since.
Elk Creek Partners's PTC Therapeutics position peaked at $17.6M in Q1 2019.
203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.